Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722804 | 0.75 | — | — | |
| SCHEMBL9720203 | 0.65 | — | — | |
| SCHEMBL862127 | 0.62 | TSHR (0.56) | TSHRHTR2CCES1 | |
| SCHEMBL862128 | 0.62 | TSHR (0.56) | TSHRHTR2CCES1 | |
| SCHEMBL4166748 | 0.62 | TSHR (0.56) | TSHRHTR2CCES1 | |
| SCHEMBL4465325 | 0.59 | TSHR (0.71) | TSHRHTR2CRETHTR2ACES1 | |
| SCHEMBL34906 | 0.59 | — | — | |
| SCHEMBL29351986 | 0.59 | — | — | |
| SCHEMBL33555 | 0.59 | — | — | |
| Bromide SCHEMBL917076 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2022-09-08 | — | — | US | claimed |
| US-10858326-B2 | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof | PURDUE PHARMA L.P. (US) | 2020-12-08 | — | — | US | claimed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | claimed |
| US-20190144400-A1 | OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2019-05-16 | — | — | US | claimed |
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | claimed |
| EP-2121641-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | claimed |
| EP-2121641-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-11-25 | — | — | EP | claimed |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-23 | — | — | US | claimed |
| WO-2008098857-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | claimed |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2022-09-08 | — | — | US | disclosed |
| US-10858326-B2 | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof | PURDUE PHARMA L.P. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190144400-A1 | OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-1832588-A1 | CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-09-12 | — | — | EP | disclosed |
| US-5925731-A | FOR TREATMENT OR PROPHYLAXIS OF ACUTE RENAL FAILURE, MYOCARDIAL INFARCTION, HEPATIC DISEASE, OR BRONCHIAL DISORDER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-20 | — | — | US | disclosed |
| EP-0852584-A1 | PEPTIDE DERIVATIVES HAVING ENDOTHELIN RECEPTOR ANTAGONISTIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997011961-A1 | PEPTIDE DERIVATIVES HAVING ENDOTHELIN RECEPTOR ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |
| US-5360568-A | 3,4-dihydroisoquinolinium salt and peroxygen compound mixture; low temperature | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1994-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | TSHR 190/4885HTR2C 180/4885PRCP 3777/4885 |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | TSHR 163/4885HTR2C 208/4885PRCP 3588/4885 |
| US-10858326-B2 | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof | OPRM1, OPRD1, CYP3A7 | TSHR 4477/4885HTR2C 303/4885PRCP 2641/4885 |
| US-20190144400-A1 | OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF | OPRM1, OPRD1, CYP3A7 | TSHR 4477/4885HTR2C 303/4885PRCP 2641/4885 |
| US-20090105307-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPSR1 | TSHR 19/4885HTR2C 61/4885PRCP 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.